Core Viewpoint - The company, Huaren Health (301408.SZ), has received a drug registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this laxative product [1]. Group 1: Product Information - The lactulose oral solution is a commonly used laxative for treating constipation, known for its ability to soften stools and regulate intestinal rhythm [1]. - Key characteristics of the product include rapid and gentle efficacy, along with high safety, making it suitable for long-term use by individuals with chronic or habitual constipation [1].

Core Viewpoint - The company, Huaren Health, has received a drug registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this commonly used laxative [1] Group 1: Company Developments - Huaren Health's wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has been granted the acceptance notice for the lactulose oral solution [1] - The lactulose oral solution is characterized by its quick and gentle laxative effect, high safety profile, and suitability for long-term use in patients with chronic or habitual constipation [1] Group 2: Industry Insights - Lactulose is a commonly used medication for treating constipation, known for its ability to soften stools and regulate intestinal function [1] - The product's features make it particularly appealing for a demographic that requires effective and safe long-term treatment options for constipation [1]

Group 1 - The core viewpoint is that Alibaba Health Technology has been a strategic investor in the company since May 2018 and continues to be one of the top ten shareholders as of September 30, 2025 [1] - The company collaborates with Alibaba Health and its associated platforms, including Alipay, Tmall, and Ele.me, to enhance its operational capabilities [1] - The company emphasizes that all operational information is disclosed through official announcements on the Giant Tide Information Network [1]

Core Viewpoint - The company Huaren Health (301408.SZ) has received a drug registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this commonly used laxative [1] Group 1: Product Overview - The lactulose oral solution is a laxative used for treating constipation, known for its ability to soften stools and regulate intestinal rhythm [1] - Key characteristics of lactulose include rapid and gentle efficacy, high safety, and suitability for long-term use in chronic or habitual constipation patients [1] Group 2: Mechanism of Action - Lactulose is metabolized in the colon by gut flora into organic acids, leading to a decrease in intestinal pH [1] - This process retains water and increases stool volume, stimulating colonic peristalsis, maintaining stool passage, alleviating constipation, and restoring the physiological rhythm of the colon [1]

Core Viewpoint - The company Huaren Health (301408.SZ) has received a registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this commonly used laxative [1] Group 1: Product Overview - The lactulose oral solution is a laxative that is commonly used to treat constipation, characterized by its ability to soften stools and regulate intestinal rhythm [1] - The product is noted for its quick and gentle effect, high safety profile, and suitability for long-term use in individuals with chronic or habitual constipation [1] Group 2: Mechanism of Action - Lactulose is metabolized in the colon by gut flora into organic acids, which lowers the pH in the intestines and retains water, thereby increasing stool volume [1] - This mechanism stimulates colonic peristalsis, ensuring smooth bowel movements and alleviating constipation while restoring the physiological rhythm of the colon [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the registration application of Lactulose Oral Solution from the National Medical Products Administration, indicating the product has entered the registration review stage [1] Group 1: Product Details - Lactulose Oral Solution is a laxative characterized by its quick, gentle, and effective action, with high safety, making it suitable for individuals with chronic or habitual constipation [1] Group 2: Regulatory Process - The acceptance of the drug registration application signifies that the product is now in the registration review phase, with completion time, approval results, and post-approval sales conditions remaining uncertain [1] Group 3: Financial Impact - The company stated that the registration application will not have a significant impact on its short-term performance [1]

证券代码：301408 证券简称：华人健康 公告编号：2025-073 安徽华人健康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 申请事项：境内生产药品注册上市许可 产品名称：乳果糖口服溶液 规格：15ml:10g 受理说明：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 受理号：CYHS250***8 二、乳果糖口服溶液的相关情况 乳果糖口服溶液是一种缓泻药，是治疗便秘的常用药，具有软化大便和调节 肠道规律的作用，主要特点是通便起效快、温和有效，安全性高，适合长期慢性 或习惯性便秘人群使用。 乳果糖在结肠中被消化道菌丛转化成有机酸，导致肠道内 pH 值下降，并通 过保留水分，增加粪便体积。上述作用刺激结肠蠕动，保持大便通畅，缓解便秘， 同时恢复结肠的生理节律。 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 近日，安徽华人健康医药股份有限公司（以下简称"公司"）全资子公司江 苏神华药业有限公司收到国家药品监督管理局下发的乳果糖口服溶液药品注册 上市许可申请《受理通知书》。现将相关情况公告如下： 一、《受理通知 ...

Group 1 - The core viewpoint of the news is that Huaren Health has shown positive financial performance and significant trading activity, indicating potential investor interest [1][2] - On December 5, Huaren Health's stock increased by 1.15%, with a trading volume of 656 million yuan, and a net financing purchase of 24.73 million yuan [1] - As of December 5, the total margin balance for Huaren Health was 183 million yuan, accounting for 7.32% of its market capitalization, which is above the 90th percentile of the past year [1] Group 2 - As of September 30, Huaren Health reported a total revenue of 3.892 billion yuan for the first nine months of 2025, representing a year-on-year growth of 19.06% [2] - The net profit attributable to the parent company for the same period was 157 million yuan, reflecting a year-on-year increase of 45.21% [2] - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [3] Group 3 - As of September 30, the number of shareholders for Huaren Health was 20,100, a decrease of 22.86% from the previous period, while the average circulating shares per person increased by 29.64% to 7,422 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the fifth largest, holding 2.3203 million shares, an increase of 1.3357 million shares compared to the previous period [3]

Market Overview - As of December 5, the Shanghai Composite Index closed at 3902.81 points, up 27.01 points, with a gain of 0.70% [1] - The Shenzhen Component Index closed at 13147.68 points, up 140.96 points, with a gain of 1.08% [1] - The ChiNext Index closed at 3109.30 points, up 41.81 points, with a gain of 1.36% [1] Stock Performance - A total of 82 A-shares had a turnover rate exceeding 20% on this day, with N-Moore-U reaching a turnover rate of over 50% [1] - N-Moore-U (688795) had a closing price of 600.50 CNY, with a turnover rate of 85.49% and a remarkable increase of 425.46% [1] - Other notable stocks with high turnover rates include: - Chuling Information (300250) with a turnover rate of 46.01% and a decline of 7.22% [1] - Sichuan Jinding (600678) with a turnover rate of 44.89% and a slight decline of 0.74% [1] - C China Uranium (001280) with a turnover rate of 44.11% and a decrease of 5.18% [1] - Jinfu Technology (003018) with a turnover rate of 43.71% and a marginal increase of 0.10% [1] Additional Notable Stocks - Weston (301315) closed at 66.30 CNY with a turnover rate of 43.08% and an increase of 5.20% [1] - Haixin Food (002702) closed at 9.55 CNY with a turnover rate of 42.20% and a gain of 10.02% [1] - Tongyu Communication (002792) closed at 29.47 CNY with a turnover rate of 41.60% and an increase of 4.73% [1] - Other stocks with significant turnover rates include: - Huawu Co., Ltd. (300095) with a turnover rate of 39.34% and a decline of 2.40% [1] - Zhongneng Electric (300062) with a turnover rate of 38.89% and an increase of 12.76% [1] - Xiaocheng Technology (300139) with a turnover rate of 38.76% and a gain of 14.62% [1]

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., has shown significant growth in revenue and net profit, indicating a positive outlook for its business operations in the pharmaceutical sector [7][8]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and went public on March 1, 2023. The company is primarily engaged in pharmaceutical agency, retail, and terminal procurement [7]. - The main revenue composition includes 97.60% from traditional Chinese and Western medicines, with the remaining 2.40% from other supplementary products [7]. - As of September 30, 2023, the company had 20,100 shareholders, a decrease of 22.86% from the previous period, with an average of 7,422 circulating shares per person, an increase of 29.64% [7]. Financial Performance - For the period from January to September 2023, the company achieved a revenue of 3.892 billion yuan, representing a year-on-year growth of 19.06% [7]. - The net profit attributable to the parent company was 157 million yuan, reflecting a year-on-year increase of 45.21% [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [9]. Market Activity - On December 5, 2023, the company's stock price increased by 1.15%, with a trading volume of 656 million yuan and a turnover rate of 26.82%, leading to a total market capitalization of 6.696 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 66.17 million yuan on the day of analysis [4][5]. Business Development - The company has established a presence on major e-commerce platforms, including JD.com, Pinduoduo, and Meituan, in addition to Alibaba's Tmall and Ele.me, indicating a broad market reach [2]. - The subsidiary Jiangsu Shenhua Pharmaceutical Co., Ltd. specializes in the research, development, and sales of fungal biopharmaceutical products, positioning itself as a pioneer in the biotechnology and new pharmaceutical sectors in China [3].